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A b s t r a c t
Background: Fast releasing, rapamycin-eluting stents, although safe, showed inferior results with regard to inhibition of restenosis. 
Aim: Therefore, we report vascular effects of a novel, biodegradable polymer stent matrix with elevated sirolimus dose and 
fast release kinetics (ed-frSES, Alex, Balton) in the porcine coronary in-stent restenosis model. 
Methods: A total of 19 stents were implanted with 120% overstretch in the coronary arteries of seven domestic pigs: seven 
ed-frSES with 1.3 μg/mm2 of sirolimus, eight frSES with 1 μg/mm2 of sirolimus, and eight bare metal stents (BMS). For the 
following 28 days, coronary angiography was performed, animals were sacrificed, and the stented segments harvested for 
histopathological evaluation.  
Results: In angiography at 28 days the late lumen loss was lowest in the elevated dose sirolimus eluting stent (SES) (ed-frSES: 
0.20 ± 0.2 vs. frSES: 0.80 ± 0.5 vs. BMS: 0.96 ± 0.5 mm, p < 0.01). This was confirmed in the morphometric evaluation 
in histopathology as represented by a significant and dose-dependent decrease in the percentage area of stenosis (ed-frSES: 
22.4 ± 12.7% vs. frSES: 35 ± 10.7% vs. BMS: 47.5 ± 12.5%, p < 0.01). There was no peri-strut inflammation in any of the 
groups. However, the endothelialisation score was numerically not meaningfully decreased in ed-frSES (ed-frSES: 2.93 vs. frSES: 
3. vs. BMS: 3, p = 0.05). Signs of fibrin were also noted in ed-frSES (ed-frSES: 0.4 vs. frSES: 0 vs. BMS: 0, p = 0.05).
Conclusions: Sirolimus dose-dependent vascular response was reported. The elevated dose, fast releasing SES shows satisfac-
tory vascular healing, similar to regular dose, fast release SES, with improved efficacy in restenosis inhibition. 
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INTRODUCTION
The balance between vascular healing process and sustained 
efficacy following percutaneous coronary intervention has 
been a challenge for nearly two decades. First-generation 
drug eluting stents (DES), although efficacious in restenosis 
inhibition when compared to bare metal stents (BMS), caused 
risk of late stent thrombosis due to increased inflammation, 
excessive fibrin deposition, and, as a consequence, impaired 
neointimal and endothelial coverage [1, 2]. Second-generation 
DES, with the utilisation of novel anti-proliferative and inflam-
matory rapamycin analogues along with biocompatible or 
biodegradable polymers, improved significantly the clinical 
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outcomes when compared to first-generation DES [3–6]. 
Additionally, it has been shown that the optimisation of drug 
release kinetics may influence the vascular response and ef-
ficacy. Early generation zotarolimus eluting stent (ZES), with 
fast release kinetics provided superior safety, with very low 
risk of stent thrombosis; however, the efficacy in restenosis 
inhibition was inferior when compared to slow-release ZES 
[7]. In our recent experiments we tested the pharmacokinetics 
of a fast-release, regular dose (1 μg/mm2) sirolimus and bio-
degradable polymer cobalt chromium stent (FR-SES), which 
has shown 95% of drug elution within 90 days in an in-vivo 
setting and complete healing at 30 days [8]; however, the 
efficacy was limited, similarly to previously cited reports on 
ZES. In the current study we test the hypothesis that sirolimus 
dose increase, as well as release kinetics, may influence the 
vascular healing response. Therefore, the dose of sirolimus on 
an identical biodegradable-polymer stent matrix was elevated 
by 30% and vascular response evaluated in the coronary 
in-stent restenosis model of a swine. 
METHODS
Device description
All stents used in this study utilised the L605 cobalt chromium 
alloy platform with a strut thickness of 70 μm and closed 
cell design, which served as a bare metal control (Coflexus, 
Balton). Sirolimus eluting stents (SES) are covered with a fully 
biodegradable multilayer structure containing a copolymer of 
poly-lactic and glycolic acid and sirolimus. The total mass of 
the polymer on a 3.0 × 15 mm stent does not exceed 360 μg. 
Experimental studies in the porcine in-stent restenosis model 
at eight weeks showed nearly full polymer biodegradation and 
95% drug release of initial drug load (Fig. 1) [8]. The studied, 
elevated dose SES (ed-frSES, Alex, Batlon, Poland) employs 
sirolimus at 1.3 μg/mm2, whereas the reference stent was at 
a regular dose of 1 μg/mm2 (frSES, regular dose, fast releasing 
sirolimus eluting stent). All stents were 3.0 mm and 3.5 mm 
in diameter and 15 mm in length. 
Study design
A study flow chart is presented in Figure 2. A total of seven 
domestic swine of both genders were included. All animals 
ranged from five to seven months of age with an average 
weight of around 45 kg at the time of enrolment. Middle 
arterial segments without side branches of all three coronary 
arteries (RCA, LAD, LCX) were screened. After live quantitative 
coronary analysis (QCA) evaluation of 21 segments 19 seg-
ments were eligible to ensure 120% overstretch for stent 
implantation and inclusion. Following randomisation of vessel 
segments in a 2:2:1 fashion, a total of eight elevated dose, 
fast-release sirolimus eluting stent (ed-frSES; study group), 
seven frSES (reference group), and four BMS controls were 
implanted with a suitable pressure required for anticipated 
overstretch diameter. Additional inflations were performed 
based upon the target site diameter. The animals were fol-
lowed up for 28 days. Subsequently, control coronary angiog-
raphy was performed and the swine were sacrificed. All arterial 
segments were dissected and harvested for pathological and 
histomorphometric analysis. All interventions and analyses 
were blinded to operators and investigators. 
Experimental procedures
The study protocol was approved by the Local Ethics Com-
mittee for animal research. All animals received a standard 
of care outlined in the study protocol and in accordance 
with the act of animal welfare and the “Principles of Care of 
Laboratory Animals” [9].
Three days prior to the procedure dual antiplatelet 
therapy consisting of 75 mg of clopidogrel and aspirin per 
day was initiated and continued until the termination. All 
pigs were fasted overnight before stent implant procedure. 
Animals were pre-medicated with atropine (0.5 mg) and 
subsequently sedated with intramuscular ketamine hydro-
chloride (20 mg/kg) and xylazine (2 mg/kg), intubated, and 
anesthetised with an intravenous propofol bolus (20–40 mg) 
followed by a continuous infusion (2–4 mg/kg/h). Electrocar-
diogram and blood pressure were continuously monitored. 
A vascular sheath (6 F) was placed in the right or left femoral 
artery utilising the Seldinger technique. Anticoagulation 
with heparin was achieved (3,000–10,000 U) to maintain 
a coagulation time ≥ 250 s. Following coronary angiography 
all coronary vessels were sized for proper stent implantation 
after live QCA analysis.
All pigs were anaesthetised and prepared in the same 
fashion as described above at 28 days following stent implan-
tation, to perform control coronary angiography, and subse-
quently humanely sacrificed with pentobarbital overdose.  
Quantitative coronary analysis 
Coronary arteries angiographies were obtained using a Siemens 
Coroskop Millenium Edition angiographic unit. A Judkins 
Right, 6 French guiding catheter was utilised to obtain coro-
Figure 1. In vivo sirolimus tissue retention expressed as percen-
tage of drug load on a stent depicting fast-release profile
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nary angiography and stent implantation. QCA analysis was 
performed in a blinded fashion using QAngio XA Software ver-
sion 7.1.14.0 (Medis Medical Imaging Systems) from two con-
tralateral projections. The baseline and 28-day follow-up ref-
erence vessel diameters (RVD) were taken from the proximal 
and distal portion of the treated segments using the guiding 
catheter as a standard for measurement. The balloon-to-artery 
ratio was calculated. The percentage diameter stenosis (%DS) 
at follow-up was calculated as: [1–(MLD/RVD)] × 100%, 
where MLD is the minimal lumen diameter.
Histological analysis
Following vessel harvesting, stented segments were immersed 
in normal buffered formalin 10%. For light microscopy all 
treated vessels were embedded in methyl methacrylate, and 
then 40–50 microns sections from the proximal, mid, and 
distal portion of each stented segment were obtained. These 
sections were stained with haematoxylin and eosin (H&E). The 
cross-sectional areas (external elastic lamina [EEL], internal 
elastic lamina [IEL] and lumen area) of each section were 
measured. Neointimal thickness was measured as the distance 
from the inner surface of the stent struts to the luminal border. 
The following measures were used to calculate vessel layer 
areas: Media = EEL – IEL; Neointima = IEL – lumen area; % 
area stenosis = [1 – (lumen area / IEL area)] × 100. All sections 
were evaluated using semi-quantitative scoring criteria. To 
evaluate the amount of injury, criteria defined by Schwartz et 
al. [10] were used: 0 = IEL intact, 1 = IEL lacerated, 2 = me-
dia lacerated, and 3 = EEL lacerated. To evaluate the extent of 
peri-strut inflammatory reaction, the following grading system 
by Kornowski et al. [11] was used: 0 = minimal inflammatory 
response around strut, 1 = few inflammatory cells around 
strut, 2 = mild to moderate inflammation, can extend into 
but do not efface surrounding tissue, and 3 = dense and thick 
peri-strut aggregate of inflammatory cells, effacing surround-
ing tissue. Each strut in the section was scored and the mean 
inflammation and injury score for each section was calculated 
and reported. The adventitial inflammation score is based on 
the following criteria: 1 = mild, 2 = moderate, and 3 = heavy 
peripheral inflammatory infiltration. The endothelialisation 
score was described as the percentage of endothelial cover-
age of the arterial circumference: 0 = < 25%, 1 = 25–75%, 
2 = 76–95%, and 3 = complete. The fibrin deposition was 
assessed as: 0 — none to focal, 1 — mild involving < 10% 
of artery circumference, 2 — moderate involving of 10–25% 
artery circumference, and 3 — heavy, involving > 25% of 
artery circumference.  
Statistical analysis
Normally distributed parametric data are expressed as aver-
age and standard deviation, and as median and interquartile 
range in cases of skewed distribution. When equal variance 
and normality were observed, one-way analysis of variance 
(ANOVA) with Student-Newman-Keuls post-ANOVA tests 
were used to test for differences in variables between stent 
types. When either equal variance test or normality test 
failed, Kruskal-Wallis test (with Dunn’s method for post-hoc 
group comparison) was conducted. A value of p ≤ 0.05 was 
considered statistically significant. MedCalc Statistical Software 
version 14.12.0 (MedCalc Software bvba, Ostend, Belgium; 
http://www.medcalc.org; 2014) was used for the data analysis.
RESULTS
Quantitative coronary angiography
A summary of the QCA analysis is presented in Table 1. The 
vessels included in the study did not differ with regard to sizes 
as shown by similar RVDs between groups. The applied stent 
balloon inflation ensured comparable 120–125% overstretch, 
Figure 2. Study flowchart; BMS — bare metal stent; ed-frSES — elevated dose, fast-release sirolimus eluting stent; frSES — regu-
lar dose, fast-release sirolimus eluting stent; QCA — quantitative coronary analysis
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acute gain, and vessel diameters after procedure. The vessel 
flow was normal in all arteries and there were no dissections 
requiring additional stent implantation. 
At 28 days the in-stent minimal lumen diameter in ed-frSES 
was higher by 20% when compared to SES (p = 0.007) and 
10% when compared to BMS (p = 0.18). This corresponded 
with %DS, which in the ed-frSES was reduced by 53% 
and 64% when compared to frSES (p = 0.002) and BMS 
(p = 0.004), respectively. Finally, the late lumen loss was also 
reduced by 75% and 80% when compared to frSES (p = 0.01) 
and BMS subsequently (p = 0.001) (Fig. 3).  
Morphometric analysis
A summary of the morphometric analysis is presented in Ta-
ble 2. In the pathological, morphometric analysis the vessels 
sizes were comparable, as shown by similar external elastic 
lamina areas between groups. Additionally, stent areas were 
also similar. The neointimal area in the ed-frSES was reduced 
by nearly 60% (p = 0.004) and 40% (p = 0.082) when com-
pared to BMS and frSES, consecutively. Correspondingly, the 
percentage area of stenosis was lowest in the ed-frSES, with 
a reduction of nearly 50% when compared to BMS (p = 0.016) 
and 35% when compared with frSES (p = 0.05). The area 
stenosis was also reduced by 27% in the frSES; however, it 
was not statistically significant (Fig. 3). 
The healing and biocompatibility profile of all tested 
devices is presented in Figure 4. The injury, peri-strut, and ad-
ventitial inflammation were modest and comparable between 
groups. Endothelialisation score was statistically significantly, 
but marginally lower (by less than 3%) in ed-frSES (ed-frSES: 
2.93 vs. frSES:3. vs. BMS: 3, p = 0.05). Similarly, the fibrin 
deposition and lipid loading severity were low, but significantly 
higher in the ed-frSES. The representative stent cross sections 
are presented in Figure 5.
DISCUSSION
In the current study we evaluate the vascular response to dif-
ferent doses of fast releasing sirolimus and biodegradable poly-
mer coated cobalt chromium stents in the porcine, coronary 
in-stent restenosis model. The elevated dose (1.3 μg/mm2) 
stent is compared with a regular dose (1 μg/mm2) reference 
stent, which both release 95% of the drug within three months 
from a biodegradable polymer platform in vivo [8]. Structur-
ally identical BMS served as a control. The correctness of 
the methodology was shown by comparable vessel sizes and 
stents enrolled. Furthermore, the induced degrees of injuries 
as expressed by the balloon-to-artery ratios were similar be-
tween the groups. At one-month follow-up the angiographic 
measures of neointimal hyperplasia (late lumen loss and 
percentage diameter stenosis) were four- and five-fold lower 
when compared to regular dose, fast-release SES and BMS, 
consecutively (p < 0.01). In the histopathological analysis, the 
Table 1. Baseline and 28-day follow-up vessel characteristics assessed by qualitative coronary angiography
frSES (n = 8) ed-frSES (n = 7) BMS (n = 4) P (ANOVA)
Baseline
RVD [mm] 2.54 ± 0.4 2.43 ± 0.2 2.86 ± 0.4 0.22
Balloon to artery ratio 1.24 ± 0.19 1.27 ± 0.1 1.20 ± 0.1 0.82
Acute gain 0.31 ± 0.4 0.32±  0.17 0.47 0.59
28 days
In MLD [mm] 2.05 ± 0.4 2.56 ± 0.2* 2.36 ± 0.6 0.01
RVD [mm] 2.50 ± 0.3 2.74 ± 0.2 2.89 ± 0.2 0.06
%DS 14.83 (12.3–21.04) 6.94* (5.75–8.30) 18.6 (11.81–43.01) 0.01
LLL [mm] 0.80 ± 0.5 0.20 ± 0.1*# 0.96 ± 0.5 0.008
*p < 0.05 for ed-SES vs. SES; #p < 0.05 for edSES vs. BMS; BMS — bare metal stent; %DS — percentage diameter stenosis; ed-frSES — elevated 
dose, fast-release sirolimus eluting stent; frSES — regular dose, fast-release sirolimus eluting stent; LLL — late lumen loss; MLD — minimal lumen 
diameter; RVD — reference vessel diameters; SES — sirolimus eluting stent
Figure 3. Angiographic and histomorphometric parameters 
representing device efficacy; BMS — bare metal stent; ed-frSES 
— elevated dose, fast-release sirolimus eluting stent; frSES —  
regular dose, fast-release sirolimus eluting stent; *p < 0.05  
for ed-frSES vs. frSES; #p < 0.05 for ed-frSES vs. BMS
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Table 2. Histopathological results of vessel morphometry, biocompatibility, and healing at 28 days of follow-up
fr-SES (n = 8) ed-frSES (n = 7) BMS (n = 4) P (ANOVA)
EEL area [mm2] 10.67 ± 1.8 9.4 ± 1.6 13.25 ± 2.7 0.021
Stent area [mm2] 7.7 ± 1 7.91 ± 1.40 9.36 ± 1.9 0.07
Lumen area [mm2] 4.49 ± 0.8 6.1 ± 1.7 4.64 ± 0.76 0.069
Neointimal area [mm2] 2.45 ± 0.9* 1.65 ± 0.7* 4.33 ± 1.7 0.003
Area of stenosis [%] 35 ± 10.7% 22.4 ± 12.7%* 47.5 ± 12.5% 0.005
*p < 0.05 vs. BMS; BMS — bare metal stent; ed-frSES — elevated dose, fast-release sirolimus eluting stent; frSES — regular dose, fast-release 
sirolimus eluting stent; EEL — external elastic lamina
Figure 4. Qualitative histopathological analysis representing healing and biocompatibility; BMS — bare metal stent; ed-frSES —  
elevated dose, fast-release sirolimus eluting stent; frSES — regular dose, fast-release sirolimus eluting stent
Figure 5. Representative histopathological stent-cross section; upper panel: stent-cross section (A. ed-frSES; B. frSES; C. BMS); 
lower panel: high power: peri-strut magnification 20×; abbreviations as in Figure 4
CA B
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reduction of late lumen loss was confirmed by significantly 
lower percentage area stenosis and neointimal area in the 
ed-frSES when compared to regular dose frSES and BMS. 
No efficacy signal in the angiographic analysis was reported 
between regular dose SES and BMS; however, in histological 
analysis the measures of neointimal hyperplasia tended to 
fall between the ed-frSES and BMS, reporting a clear dose 
dependent effect. Interestingly, despite higher dose of eluted 
sirolimus, healing expressed as endothelialisation, fibrin depo-
sition, although numerically in favour of regular dose frSES 
and BMS, seems to be very satisfactory. Slightly decreased 
endothelialisation score and signs of fibrin deposition in the 
ed-frSES are well-described signatures of vascular response to 
the sirolimus [2] and also support the notion of dose effect. 
The optimisation of vascular response and clinical 
outcome of DES technologies is dependent upon multiple 
factors. The utilisation of biodegradable and biocompatible 
polymers has shown theoretical advantages in vitro and in 
the experimental setting [12]; however, the clinical benefit, 
especially when compared with second-generation durable 
polymer counterparts, is inconclusive [13). It seems that the 
type of drug, and specifically modification of the release pro-
file, plays more pronounced role. Fast-release ZES (Endeavour, 
Medtronic) has shown a significant difference in clinical per-
formance against paclitaxel-eluting stents (PES), as shown by 
significant risk reduction in late and very late stent thrombosis, 
cardiac death, and myocardial infarction [14, 15]. On the other 
hand, at longer follow-up the excellent safety profile did not 
translate into efficacy, with inferior rates of angiographic sur-
rogates of restenosis and target vessel failure when compared 
to SES and PES [15–17]. Following these results, fast-release ZES 
were replaced by slow-release counterparts yielding improved 
neointimal inhibition [7] and non-inferior clinical outcomes 
when compared to everolimus eluting stents [18]. 
Therefore, in the current study, to the best of our knowl-
edge for the first time, we evaluate the biological effect of 
an elevated dose of sirolimus deployed on a fast-release 
biodegradable-polymer stent matrix. This concept was chosen 
to combine the preferable safety of fast sirolimus release kinet-
ics and the efficacy of long-term tissue retention. Previously, 
a similar effect and reduction of delayed healing was observed 
by lowering the sirolimus dose from the hydroxyapatite, 
slow-release matrix [19]. Also, a positive vascular effect has 
been accomplished in the Endeavor Resolute stent, by poly-
mer design modification, and as a consequence the release 
kinetics. Slow-release ZES has demonstrated less late lumen 
loss but similar biocompatibility to BMS and fast-release ZES 
[20–22]. In our approach the vascular effect (restenosis inhi-
bition) was achieved with a sirolimus dose elevation of 30%, 
which is contrary to previous reports in which mathematical 
modelling predicted that an increase in sirolimus dose and 
elution would not affect the sirolimus receptor binding ca-
pabilities, and as a consequence the biological effect [23]. 
In our study, a clear dose-dependent neointimal inhibition 
effect was reported. This result contrary to the previously-cited 
study might be explained by the analytical rather than empiri-
cal methodology and multifactorial mechanism of action of 
sirolimus [24].
The safety and efficacy of a studied fr-edSES (Alex, Balton) 
was shown in the first-in-man study [25], in which temporal 
vascular healing was evaluated with serial Optical Coherence 
Tomography (OCT) evaluation. The favourable healing profile 
was confirmed at three months, at which time 97% of struts 
were covered by neointima. The efficacy was sustained until 
12 months with in-stent late-lumen loss of 0.14 mm. Longer 
follow-up in the clinical setting is required to establish a full 
safety profile of the studied stent.
Limitations of the study
The limitations of this study include the nature of the experi-
mental preclinical model as a human clinical surrogate and 
utilisation of a healthy domestic swine, without underlying 
disease. Furthermore, no intravascular imaging was utilised to 
prevent injury to endothelium caused by mechanical pullback 
to provide unbiased histopathological results. Histopathologi-
cal evaluation was performed with H&E staining only.
CONCLUSIONS
In conclusion, the dose-dependent vascular effect of sirolimus, 
rapidly eluted from the biodegradable polymer and stent ma-
trix, was observed. The ed-frSES provided efficacious neoin-
timal hyperplasia inhibition when compared to regular dose 
frSES; however, the healing was satisfactory. These findings 
support the notion that not only drug release kinetics, but also 
the dose of the eluted drug influences the biological response. 
The clinical implications are important. The combination 
of fast release kinetics and dose-efficient sirolimus delivery 
from the stent and biodegradable platform contributes to early 
strut coverage and healing, as shown in the first-in-man OCT 
study. In future this may significantly shorten the duration of 
double antiplatelet therapy.
Acknowledgements
This study was supported by unrestricted research grant from 
Balton Company, Warsaw, Poland.
Conflict of interest: Piotr P. Buszman — unrestricted research 
grants, Balton, Warsaw, Poland; Krzysztof Milewski — unrestrict-
ed research grants and consultancy, Balton, Warsaw, Poland.
References
1. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after 
implantation of first-generation drug-eluting stents: a cause for 
concern. Circulation, 2007; 115: 1440–1455.
2. Nakazawa G, Finn AV, John MC et al. The significance of preclini-
cal evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting 
stents. Am J Cardiol, 2007; 100: 36M–44M.
3. Stone GW, Midei M, Newman W et al. Comparison of an everoli-
mus-eluting stent and a paclitaxel-eluting stent in patients with 
www.kardiologiapolska.pl
Piotr P. Buszman et al.
922
Cite this article as: Buszman PP, Orlik B, Pająk J et al. Dose-dependent vascular response following delivery of sirolimus via fast releas-
ing, biodegradable polymer stent matrix: an experimental study in the porcine coronary model of restenosis. Kardiol Pol, 2015; 73: 
916–923. doi: 10.5603/KP.a2015.0085.
coronary artery disease: a randomized trial. JAMA, 2008; 299: 
1903–1913. doi: 10.1001/jama.299.16.1903.
4. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting 
stent with biodegradable polymer versus sirolimus-eluting stent 
with durable polymer for coronary revascularisation (LEAD-
ERS): a randomised non-inferiority trial. Lancet, 2008; 372: 
1163–1173. doi: 10.1016/S0140-6736(08)61244-1.
5. Stefanini GG, Byrne RA, Serruys PW et al. Biodegradable polymer 
drug-eluting stents reduce the risk of stent thrombosis at 4 years 
in patients undergoing percutaneous coronary intervention: 
a pooled analysis of individual patient data from the ISAR-TEST 
3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J, 
2012; 33: 1214–1222. doi: 10.1093/eurheartj/ehs086.
6. Stefanini GG, Kalesan B, Serruys PW et al. Long-term clinical 
outcomes of biodegradable polymer biolimus-eluting stents 
versus durable polymer sirolimus-eluting stents in patients with 
coronary artery disease (LEADERS): 4 year follow-up of a ran-
domised non-inferiority trial. Lancet, 2011; 378: 1940–1948. doi: 
10.1016/S0140-6736(11)61672-3.
7. Guagliumi G, Ikejima H, Sirbu V et al. Impact of drug release 
kinetics on vascular response to different zotarolimus-eluting 
stents implanted in patients with long coronary stenoses: the 
LongOCT study (Optical Coherence Tomography in Long Le-
sions). J Am Coll Cardiol Cardiovasc Interv, 2011; 4: 778–785. doi: 
10.1016/j.jcin.2011.04.007.
8. Orlik B, Buszman PP, Jelonek M et al. TCT-813 A novel method 
for evaluation of polymer absorption from sirolimus eluting 
stent and its influence on biological effects. J Am Coll Cardiol, 
2013; 62: B246.
9. Institute of Laboratory Animal Resources NRC. Principles of 
Care of Laboratory Animals. NIH Publication 1996; No. 85–23.
10. Schwartz RS, Huber KC, Murphy JG et al. Restenosis and the 
proportional neointimal response to coronary artery injury: 
results in a porcine model. J Am Coll Cardiol, 1992; 19: 267–274.
11. Kornowski R, Hong MK, Tio FO et al. In-stent restenosis: 
contributions of inflammatory responses and arterial injury to 
neointimal hyperplasia. J Am Coll Cardiol, 1998; 31: 224–230.
12. Eppihimer MJ, Sushkova N, Grimsby JL et al. Impact of stent 
surface on thrombogenicity and vascular healing: a comparative 
analysis of metallic and polymeric surfaces. Circ Cardiovasc 
Interv, 2013; 6: 370–377. doi: 10.1161/CIRCINTERVEN-
TIONS.113.000120.
13. Palmerini T, Biondi-Zoccai G, Della Riva D et al. Clinical 
outcomes with bioabsorbable polymer- versus durable poly-
mer-based drug-eluting and bare-metal stents: evidence from 
a comprehensive network meta-analysis. J Am Coll Cardiol, 2014; 
63: 299–307. doi: 10.1016/j.jacc.2013.09.061.
14. Kirtane AJ, Leon MB, Ball MW et al. The “final” 5-year follow-up 
from the ENDEAVOR IV trial comparing a zotarolimus-eluting 
stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv, 
2013; 6: 325–333. doi: 10.1016/j.jcin.2012.12.123. 
15. Leon MB, Mauri L, Popma JJ et al. A randomized comparison 
of the Endeavor zotarolimus-eluting stent versus the TAXUS 
paclitaxel-eluting stent in de novo native coronary lesions 
12-month outcomes from the ENDEAVOR IV trial. J Am Coll 
Cardiol, 2010; 55: 543–554. doi: 10.1016/j.jacc.2009.08.067.
16. Kandzari DE, Leon MB, Popma JJ et al. Comparison of zotaroli-
mus-eluting and sirolimus-eluting stents in patients with native 
coronary artery disease: a randomized controlled trial. J Am Coll 
Cardiol, 2006; 48: 2440–2447.
17. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Car-
diol, 2010; 56 (10 suppl.): S1–S42. doi: 10.1016/j.jacc.2010.06.007.
18. Serruys PW, Silber S, Garg S et al. Comparison of zotarolim-
us-eluting and everolimus-eluting coronary stents. N Engl J Med, 
2010; 363: 136–146. doi: 10.1056/NEJMoa1004130.
19. van der Giessen WJ, Sorop O, Serruys PW et al. Lowering the 
dose of sirolimus, released from a nonpolymeric hydroxyapatite 
coated coronary stent, reduces signs of delayed healing. J Am 
Coll Cardiol Cardiovasc Interv, 2009; 2: 284–290. doi: 10.1016/j.
jcin.2008.12.012.
20. Udipi K, Chen M, Cheng P et al. Development of a novel 
biocompatible polymer system for extended drug release in 
a next-generation drug-eluting stent. J Biomed Mater Res A, 
2008; 85: 1064–1071.
21. Resolute Integrity Zotarolimus-Eluting Coronary Stent System. 
Summary of Safety and Effectiveness Data. 2011.
22. Udipi K, Melder RJ, Chen M et al. The next generation Endeavor 
Resolute Stent: role of the BioLinx Polymer System. EuroInter-
vention, 2007; 3: 137–139. 
23. Tzafriri AR, Groothuis A, Price GS, Edelman ER. Stent elu-
tion rate determines drug deposition and receptor-mediated 
effects. J Control Release, 2012; 161: 918–926. doi: 10.1016/j.
jconrel.2012.05.039.
24. Costa MA, Simon DI. Molecular basis of restenosis and drug-elut-
ing stents. Circulation, 2005; 111: 2257–2273.
25. Legutko JG, Robert J, Buszman PE. TCT-565 OCT evaluation of 
the time course of vessel healing following implantation of new 
generation biodegradable polymer-coated and sirolimus-eluting 
cobalt-chromium coronary stent system (ALEX OCT Study). 
J Am Coll Cardiol, 2013; 62: B170–B171.
www.kardiologiapolska.pl 923
Adres do korespondencji: 
dr hab. n. med. Piotr P. Buszman, Centrum Badawczo-Rozwojowe American Heart of Poland SA, ul. Czajek 41, 40–534 Katowice, e-mail: p.buszman@ahp-ccrd.org 
Praca wpłynęła: 04.11.2014 r. Zaakceptowana do druku: 31.03.2015 r. Data publikacji AoP: 28.04.2015 r.
Zależna od dawki odpowiedź ściany naczyniowej 
na implantację stentu szybko uwalniającego lek, 
pokrytego polimerem biodegradowalnym  
ze zwiększoną dawką sirolimusa:  
badanie eksperymentalne na modelu restenozy 
tętnic wieńcowych świni domowej
Piotr P. Buszman1, Bartłomiej Orlik1, Jacek Pająk2, Michał Jelonek1, Agata Krauze1, Adam Janas1,  
Jacek Legutko3, Wojciech Wojakowski2, Paweł E. Buszman1, Krzysztof Milewski1
1Centrum Badawczo-Rozwojowe American Heart of Poland SA, Katowice
2Śląski Uniwersytet Medyczny, Katowice
3Zakład Hemodynamiki i Angiokardiografii, Collegium Medicum, Uniwersytet Jagielloński, Szpital Uniwersytecki, Kraków
S t r e s z c z e n i e
Wstęp: Chociaż stenty powlekane analogami rapamycyny o szybkim profilu uwalniania leku udowodniły swoje bezpieczeń-
stwo, to ich skuteczność w zapobieganiu restenozie jest niewystarczająca. 
Cel: Celem pracy była ocena efektów tkankowych w odpowiedzi na implantację stentu szybko uwalniającego lek, pokrytego 
polimerem biodegradowalnym ze zwiększoną dawką sirolimusa (ed-frSES, Alex, Balton) z wykorzystaniem modelu restenozy 
tętnic wieńcowych świni domowej.
Metody: Wszczepiono 19 stentów ze 120% przerozmiarowaniem (tzw. overstretch) do tętnic wieńcowych 7 świń domowych: 
7 stentów typu ed-frSES z 1,3 μg/mm2 sirolimusa, 8 stentów szybko uwalniających lek ze standardową dawką sirulimusa (frSES) 
i 8 stentów metalowych (BMS). Po 28 dniach obserwacji wykonano angiografię z oceną ilościową. Następnie zwierzęta zostały 
poddane eutanazji, a badane segmenty wypreparowane w celu przeprowadzenia analizy histopatologicznej.
Wyniki: Po 28 dniach późna utrata światła w ocenie angiograficznej była najniższa w grupie ze zwiększoną dawką sirolimusa 
(ed-frSES: 0,20 ± 0,2 vs. frSES: 0,80 ± 0,5 vs. BMS: 0,96 ± 0,5 mm; p < 0,01). Podobne wyniki uzyskano w analizie hi-
stopatologicznej, w której obserwowano istotnie mniejsze procentowe zwężenie pola przekroju w grupie ed-frSES (ed-frSES: 
22,4 ± 12,7% vs. frSES: 35 ± 10,7% vs. BMS: 47,5 ± 12,5%; p < 0,01). W żadnej z badanych grup nie zaobserwowano 
okołoprzesłowego nacieku zapalnego. Poziom endotelializacji był nieco mniejszy w grupie ed-frSES, jednak różnica ta nie 
była istotna statystycznie (ed-frSES: 2,93 vs. frSES: 3. vs. BMS: 3; p = 0,05). Ponadto w grupie ed-frSES zaobserwowano 
okołoprzesłowo nieznaczną ilość włóknika (ed-frSES: 0,4 vs. frSES: 0 vs. BMS: 0; p = 0,05).
Wnioski: Potwierdzono zależną od dawki sirolimusa odpowiedź tkankową. Stenty szybko uwalniające lek ze zwiększoną 
dawką sirolimusa (ed-frSES) umożliwiają zadowalające gojenie się ściany naczyniowej, podobne do stentów ze standardową 
dawką leku, przy jednocześnie skuteczniejszym hamowaniu restenozy.
Słowa kluczowe: stenty uwalniające sirolimus, szybkie uwalnianie, polimer biodegradowalny, model tętnic wieńcowych świni
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